ArticleNature reviews. Cardiology2011

Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial.

Gregory B LimPubMed ↗Publisher ↗

No numbers read from the abstract.